Scientists conducted the first tests of a new vaccine from COVID-19, developed on the basis of a drug from another MERS-CoV coronavirus, which causes the Middle East respiratory syndrome. This is stated in a statement by specialists from the University of Georgia.
Scientists from the University of Georgia are the creators of a vaccine for another coronavirus, so now they are trying to create a successful vaccine against SARS-CoV-2 based on this drug. Now the new MERS vaccine has successfully passed the first tests to increase immunity to COVID-19 in the laboratory.
Both vaccines are based on a viral delivery platform that contains modified strains of the PIV5 virus that causes dogs to cough. These modified viruses produce spike proteins found in two coronaviruses, which form the so-called corona, after which this type of virus is named.
After the introduction of viruses safe for humans with the corona, the body begins to defend itself against these proteins, as a result of which the cells increase their resistance to this type of infection. At the same time, PIV5 is excreted from the body within a few days, however, the immunity in the cells remains for a long time.
If clinical trials are successful, a vaccine based on this technology may be ready by the end of 2020.